Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study. Poster presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum; February 27-29, 2020; West Palm Beach, FL.
 Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: ECTRIMS; September 2016; London, UK.
 Hauser SL, et al. Presented at ECTRIMS 2019. OP336.
90% 对应 - Data on file. OMB157G (ofatumumab) OMB157G 126.96.36.199. Statistical overview. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019.